Autonomix Medical, Inc.
AMIX Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2023–FY2026
Revenue
Total sales reported in the income statement.
$0.0M
vs prior year
Operating margin
Operating income as a share of revenue.
—
Net income
Profit after all expenses, interest and tax.
−$16.7M
Free cash flow
Cash from operations minus capital spending.
−$12.3M
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap
Last close times the latest diluted share count, so it is approximate.
—
P/E
Last close divided by diluted earnings per share over the last four quarters.
—
What Autonomix Medical, Inc. does
No business description yet.
- Legal name
- Autonomix Medical, Inc.
- Fiscal year ends
- March 31, 2026
- Latest annual report
- 10-K · May 27, 2026
- Accession · CIK
- 0001437749-26-018573
0001617867
Revenue and margins
Autonomix Medical, Inc. had $0.0M of revenue in fiscal 2026.
FY23
Revenue $0.0M
FY24
Revenue $0.0M
FY25
Revenue $0.0M
FY26
Revenue $0.0M
Q2 '24
Revenue $0.0M
Q3 '24
Revenue $0.0M
Q4 '24
Revenue $0.0M
Q1 '25
Revenue $0.0M
Q2 '25
Revenue $0.0M
Q3 '25
Revenue $0.0M
Q4 '25
Revenue $0.0M
Q1 '26
Revenue $0.0M
Q2 '26
Revenue $0.0M
Q3 '26
Revenue $0.0M
Q4 '26
Revenue $0.0M
Q1 '27
Revenue $0.0M
FY23
Gross —
Operating —
Net —
FCF —
FY24
Gross —
Operating —
Net —
FCF —
FY25
Gross —
Operating —
Net —
FCF —
FY26
Gross —
Operating —
Net —
FCF —
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY23
Net income −$2.0M
FY24
Net income −$15.4M
FY25
Net income −$11.4M
FY26
Net income −$16.7M
Q2 '24
Net income −$6.0M
Q3 '24
Net income −$3.1M
Q4 '24
Net income −$15.4M
Q1 '25
Net income −$2.7M
Q2 '25
Net income −$2.8M
Q3 '25
Net income −$2.7M
Q4 '25
Net income −$11.4M
Q1 '26
Net income −$3.3M
Q2 '26
Net income −$7.5M
Q3 '26
Net income −$3.3M
Q4 '26
Net income −$2.7M
Q1 '27
Net income −$2.7M
FY23
Diluted EPS —
FY24
Diluted EPS —
FY25
Diluted EPS —
FY26
Diluted EPS —
Q2 '24
Diluted EPS —
Q3 '24
Diluted EPS −$0.23
Q4 '24
Diluted EPS —
Q1 '25
Diluted EPS —
Q2 '25
Diluted EPS —
Q3 '25
Diluted EPS —
Q4 '25
Diluted EPS —
Q1 '26
Diluted EPS —
Q2 '26
Diluted EPS —
Q3 '26
Diluted EPS —
Q4 '26
Diluted EPS —
Q1 '27
Diluted EPS —
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY23
Return on capital —
Return on equity −309.0%
Return on assets −230.1%
FY24
Return on capital —
Return on equity −373.0%
Return on assets −300.4%
FY25
Return on capital —
Return on equity −145.1%
Return on assets −118.8%
FY26
Return on capital —
Return on equity −238.9%
Return on assets −192.1%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was −$12.3M in fiscal 2026, — of revenue. Cash from operations minus capital spending.
FY23
Free cash flow −$1.9M
FY24
Free cash flow −$6.6M
FY25
Free cash flow −$8.3M
FY26
Free cash flow −$12.3M
Q2 '24
Free cash flow −$1.1M
Q3 '24
Free cash flow −$2.6M
Q4 '24
Free cash flow −$6.7M
Q1 '25
Free cash flow −$1.9M
Q2 '25
Free cash flow −$1.6M
Q3 '25
Free cash flow −$2.3M
Q4 '25
Free cash flow −$8.3M
Q1 '26
Free cash flow −$2.6M
Q2 '26
Free cash flow −$3.8M
Q3 '26
Free cash flow −$3.0M
Q4 '26
Free cash flow −$2.9M
Q1 '27
Free cash flow —
FY23
Cash from operations −$1.9M
Capital spending $0.0M
FY24
Cash from operations −$6.6M
Capital spending $0.0M
FY25
Cash from operations −$8.3M
Capital spending $0.0M
FY26
Cash from operations −$12.3M
Capital spending $0.0M
Cash from operations
Capital spending
Q2 '24
Cash from operations −$1.1M
Capital spending $0.0M
Q3 '24
Cash from operations −$2.6M
Capital spending $0.0M
Q4 '24
Cash from operations −$6.6M
Capital spending $0.0M
Q1 '25
Cash from operations −$1.9M
Capital spending $0.0M
Q2 '25
Cash from operations −$1.6M
Capital spending $0.0M
Q3 '25
Cash from operations −$2.3M
Capital spending $0.0M
Q4 '25
Cash from operations −$8.3M
Capital spending $0.0M
Q1 '26
Cash from operations −$2.6M
Capital spending $0.0M
Q2 '26
Cash from operations −$3.8M
Capital spending $0.0M
Q3 '26
Cash from operations −$3.0M
Capital spending $0.0M
Q4 '26
Cash from operations −$2.9M
Capital spending $0.0M
Q1 '27
Cash from operations −$3.5M
Capital spending —
Cash from operations
Capital spending
Dividends, buybacks and share count
Autonomix Medical, Inc. returned — to shareholders in fiscal 2026. The diluted share count rose 0.0%.
FY23
Dividends —
Buybacks —
FY24
Dividends —
Buybacks —
FY25
Dividends —
Buybacks —
FY26
Dividends —
Buybacks —
Dividends
Buybacks
FY23
Diluted shares —
FY24
Diluted shares —
FY25
Diluted shares —
FY26
Diluted shares —
Balance sheet
Cash, debt and the ratios that show how comfortably Autonomix Medical, Inc. can carry it.
FY23
Cash $0.9M
Debt $0.0M
FY24
Cash $8.6M
Debt $0.0M
FY25
Cash $9.1M
Debt —
FY26
Cash $7.0M
Debt —
Cash
Debt
| Fiscal year end | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Cash and short-term investments | $0.9M | $8.6M | $9.1M | $7.0M |
| Debt incl. finance leases | $0.0M | $0.0M | — | — |
| Debt / equity | 0.0x | 0.0x | — | — |
| Interest coverage | — | −152.3x | −65.8x | — |
| Current ratio | 3.9x | 12.1x | 5.6x | 4.4x |
| Quick ratio | 3.9x | 12.1x | 5.6x | 4.4x |
| Total assets | $0.9M | $9.4M | $9.8M | $7.6M |
| Total liabilities | $0.2M | $1.8M | $1.7M | $1.7M |
| Shareholders' equity | $0.6M | $7.6M | $8.1M | $5.9M |
| Net debt (− = net cash) | −$0.9M | −$8.6M | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✓ | ✓ | ✕ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ | ✓ |
| Debt fell relative to assets | — | ✕ | — | — |
| Current ratio rose | — | ✓ | ✕ | ✕ |
| Share count didn't rise | — | — | — | — |
| Gross margin rose | — | — | — | — |
| Revenue rose relative to assets | — | ✕ | ✕ | ✕ |
| F-score | — / 3 | 3 / 7 | — / 6 | — / 6 |
| Accruals ratio | −15.7% | −171.8% | −32.8% | −50.9% |
| Altman Z'' | −96.24 | −11.59 | −14.42 | −35.14 |
4 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Research and development | $0.7M | $2.2M | $4.7M | $7.1M |
| Operating income | −$2.0M | −$12.0M | −$11.6M | −$17.0M |
| Interest expense | $0.0M | $0.1M | $0.2M | $0.0M |
| Pretax income | −$2.0M | −$15.4M | −$11.4M | −$16.7M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | −$2.0M | −$15.4M | −$11.4M | −$16.7M |
| Cash flow | ||||
| Cash from operations | −$1.9M | −$6.6M | −$8.3M | −$12.3M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$1.9M | −$6.6M | −$8.3M | −$12.3M |
| Depreciation and amortization | $0.0M | $0.1M | $0.2M | $0.0M |
| Stock-based compensation | $0.0M | $0.6M | $1.6M | $0.5M |
| Balance sheet | ||||
| Cash and short-term investments | $0.9M | $8.6M | $9.1M | $7.0M |
| Total debt | $0.0M | $0.0M | — | — |
| Current assets | $0.9M | $9.4M | $9.6M | $7.6M |
| Current liabilities | $0.2M | $0.8M | $1.7M | $1.7M |
| Property and equipment, net | $0.0M | $0.0M | $0.0M | $0.0M |
| Total assets | $0.9M | $9.4M | $9.8M | $7.6M |
| Total liabilities | $0.2M | $1.8M | $1.7M | $1.7M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $0.6M | $7.6M | $8.1M | $5.9M |
| Returns | ||||
| Return on capital employed | −309.0% | −139.4% | −143.1% | −289.0% |
| Return on equity | −309.0% | −373.0% | −145.1% | −238.9% |
| Return on assets | −230.1% | −300.4% | −118.8% | −192.1% |
| Return on tangible equity | −309.0% | −202.2% | −140.9% | −283.5% |
| Financial health | ||||
| Debt / equity | 0.0x | 0.0x | — | — |
| Interest coverage | — | −152.3x | −65.8x | — |
| Current ratio | 3.9x | 12.1x | 5.6x | 4.4x |
| Quick ratio | 3.9x | 12.1x | 5.6x | 4.4x |
| Quality scores | ||||
| Piotroski F-score | — | 3.0 | — | — |
| Altman Z'' | −96.2 | −11.6 | −14.4 | −35.1 |
| Accruals ratio | −15.7% | −171.8% | −32.8% | −50.9% |
Source: SEC EDGAR XBRL filings (CIK 0001617867). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.